Ni iyihe mikorere y'umubiri w'indwara ya kanseri y'ibihaha?
Imikorere y'umubiri w'umurwayi wa kanseri y'ibihaha yerekeza ku mpinduka mu mikorere isanzwe n'imikorere y'umubiri ibaho mu mikurire n'iterambere ry'indwara ya kanseri y'ibihaha.
Kanseri y'ibihaha ni indwara itoroshye iterwa n'ubwiyongere no kwigabanyamo kw'uturemangingo tudasanzwe mu bihaha.
Imikorere y'indwara ya kanseri y'ibihaha irimo ibintu byinshi, harimo impinduka mu ngirabuzima fatizo, ibidukikije n'uburyo bwo kubaho.
Impinduka mu miterere y'uturemangingo zishobora kubaho muri ADN y'uturemangingo two mu bihaha, bigatuma turushaho gukura no kwigabanyamo ibice byinshi.
Izo mpinduka zishobora guturuka ku babyeyi cyangwa ku muntu, kandi zishobora guterwa no guhura n'ibintu bitera kanseri, urugero nk'umwotsi w'itabi, ubumara bwitwa radon, amiante n'umwuka uhumanye.
Kanseri y'ibihaha ishobora gushyirwa mu byiciro bibiri by'ingenzi: kanseri y'ibihaha y'ingirabuzimafatizo nto (SCLC) na kanseri y'ibihaha y'ingirabuzimafatizo nto (NSCLC). NSCLC igabanyijemo ibyiciro bitatu: adenocarcinoma, squamous cell carcinoma, na large cell carcinoma.
Imikorere y'ibi bice by'umubiri w'ibi bihaha ishobora gutandukana, kuko bifite uturemangingo dutandukanye kandi bikira ku buryo butandukanye ku miti.
Imikorere y'umubiri w'indwara ya kanseri y'ibihaha inakubiyemo imikoranire hagati y'uturemangingo twa kanseri n'ingingo zikikije, harimo n'abasirikare b'umubiri.
Ingirabuzimafatizo za kanseri zishobora kwihunza ubudahangarwa bw'umubiri, bigatuma zikura kandi zikwirakwira nta nkomyi.
Byongeye kandi, mikorobe y'igifu ishobora gutuma ikura kandi igatera kanseri mu mubiri binyuze mu guha ingirabuzimafatizo za kanseri ahantu ho kuba.
Imikorere y'indwara ya kanseri y'ibihaha ni inzira igoye kandi ihinduka, kandi abashakashatsi bahora bakora kugira ngo barusheho gusobanukirwa imikorere y'ingenzi yo kuvumbura uburyo bwiza bwo kuvura no kunoza ibisubizo by'abarwayi.
Li Z, Qian Y, Li W, Liu L, Yu L, Liu X, Wu G, Wang Y, Luo W, Fang F, Liu Y, Song F, Cai Z, Chen W, Huang W: Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening. iScience. 2020, 23 (8): 101411.
Nurwidya F, Syahruddin E, Yunus F: Pain management in lung cancer. Adv Respir Med. 2016, 84 (6): 331-336.
Khan KA, Kennedy MP, Moore E, Crush L, Prendeville S, Maher MM, Burke L, Henry MT: Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung. 2015, 193 (1): 71-7.
Paramanantham A, Asfiya R, Das S, McCully G, Srivastava A: Extracellular Vesicle (EVs) Associated Non-Coding RNAs in Lung Cancer and Therapeutics. Int J Mol Sci. 2022, 23 (21): .
Lee D, Kim Y, Chung C: Scientific Validation and Clinical Application of Lung Cancer Organoids. Cells. 2021, 10 (11): .
Mucchietto V, Crespi A, Fasoli F, Clementi F, Gotti C: Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment. Curr Pharm Des. 2016, 22 (14): 2160-9.
["Buri gihe ujye usaba inama umuganga wawe cyangwa undi muntu wemewe mu bijyanye n'ubuzima ku bijyanye n'uburwayi. Ntuzigere wirengagiza inama z'abaganga cyangwa ngo utinde kuzisaba bitewe n'ikintu wasomye kuri uru rubuga. Niba utekereza ko ufite ikibazo cyihutirwa, hamagara 911 cyangwa ujye ku ivuriro rikwegereye. Nta mubano hagati y'umuganga n'umurwayi ukorwa n'uru rubuga cyangwa ikoreshwa ryarwo. Yaba BioMedLib cyangwa abakozi bayo, cyangwa undi muntu wese wagize uruhare kuri uru rubuga, nta gihamya batanga, yaba igaragara cyangwa itagaragara, ku bijyanye n'amakuru atangwa hano cyangwa ikoreshwa ryayo."]
["Ibirego: uburenganzira bw'umuhanzi"]
["Itegeko ryo mu 1998 ryerekeye uburenganzira bw'ibihumbi by'ibihumbi by'ibihumbi by'ibihumbi, 17 U.S.C. § 512 (DMCA) ritanga ubujurire ku bafite uburenganzira bw'umuhanzi bemera ko ibintu bigaragara kuri interineti bibangamira uburenganzira bwabo hakurikijwe amategeko y'uburenganzira bw'umuhanzi muri Amerika. "]
['Niba wemera ko ibintu cyangwa ibikoresho byashyizwe ku rubuga rwacu cyangwa serivisi bitubahiriza uburenganzira bwawe, wowe (cyangwa umuhagarariye) ushobora kutwoherereza ubutumwa udusaba ko ibyo bintu cyangwa ibikoresho bikurwaho, cyangwa ko utabikoresha.']
['Itangazo rigomba koherezwa mu nyandiko kuri interineti (reba ahanditse "Kwitaba" kugira ngo ubone aderesi ya interineti). ']
["DMCA isaba ko imenyesha ryawe ry'ikirego cyo kuvutswa uburenganzira rikubiyemo amakuru akurikira: (1) ibisobanuro by'igikorwa kirengera uburenganzira bw'umuhanzi kivugwaho kuvutswa uburenganzira; (2) ibisobanuro by'ibikubiyemo bivugwa ko ari ukurenga ku mategeko n'amakuru ahagije atuma dushobora kubona ibikubiyemo; (3) amakuru yo kuguhamagaraho, harimo aderesi yawe, nomero ya terefone na aderesi imeyiri; (4) inyandiko yawe ivuga ko ufite icyizere ko ibikubiyemo mu buryo bwatanzwe nta burenganzira bifite na nyiri uburenganzira bw'umuhanzi, cyangwa umukozi we, cyangwa mu mategeko ayo ari yo yose; "]
["(5) inyandiko yawe isinyweho, uhanishwa kubeshya, yemeza ko amakuru ari mu itangazo ari ukuri kandi ko ufite ububasha bwo kurengera uburenganzira bw'umuhanzi uvugwaho kubwamburwa; "]
["kandi (6) umukono usanzwe cyangwa wa elegitoroniki w'ufite uburenganzira ku nyandiko cyangwa uw'umuntu wabiherewe uburenganzira bwo gukora mu izina ry'ufite uburenganzira ku nyandiko. "]
The pathophysiology of lung cancer refers to the changes in the normal physiological processes and mechanisms that occur in the development and progression of lung cancer.
Lung cancer is a complex disease that arises from the uncontrolled growth and division of abnormal cells in the lungs.
These cells can form tumors and spread to other parts of the body, leading to various symptoms and complications.
The pathophysiology of lung cancer involves several factors, including genetic mutations, environmental factors, and lifestyle choices.
Genetic mutations can occur in the DNA of lung cells, leading to uncontrolled cell growth and division.
These mutations can be inherited or acquired, and they can be caused by exposure to carcinogens, such as tobacco smoke, radon, asbestos, and air pollution.
Lung cancer can be classified into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is further divided into three subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
The pathophysiology of these types of lung cancer can differ, as they have different genetic mutations and respond differently to treatment.
The pathophysiology of lung cancer also involves the interaction between cancer cells and the surrounding tissue, including the immune system.
Cancer cells can evade the immune system, allowing them to grow and spread unchecked.
Additionally, the tumor microenvironment can promote tumor growth and metastasis by providing a supportive environment for cancer cells.
The pathophysiology of lung cancer is a complex and dynamic process, and researchers are continuously working to better understand the underlying mechanisms to develop more effective treatments and improve patient outcomes.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Kubijyanye']
["BioMedLib ikoresha mudasobwa zikoresha ikoranabuhanga mu gukora ibibazo n'ibisubizo."]
["Twatangiriye ku bitabo bya siyansi bivuga iby'ubuvuzi bigera kuri miriyoni 35 byo mu nkoranyamagambo yitwa PubMed/Medline."]
['Reba "Inyandiko z\'ibanze" na "Inyandiko y\'ibanze".']
